MHRA may allow drug reaction reporting through social media

Tuesday, September 13, 2011 01:23 PM

Drug reaction reporting from smartphones, Facebook and Twitter is being considered after the success of a scheme allowing direct reporting from GP practice IT systems, according to GP Online.

The MHRA is now “actively working on introducing other ways of reporting to make it easier and encourage more reporting.”

Mick Foy, group manager for vigilance and risk management of medicines at the MHRA, said, “Applications for smartphones, improved web reporting forms and the use of social media such as Twitter and Facebook are being carefully considered as potential routes for reporting.”

Valid reports have to contain information on the drug, reaction, patient and reporter, and allow the agency to follow-up reports, he continued.

“It is important to consider the structure of the information for inclusion on our database, something Twitter and Facebook do not easily lend themselves to,” said Foy.

Plans to expand submission of yellow cards follow the agency’s launch of direct reporting from practice IT systems in order to increase reports from GPs.

The 1,100 GP practices using the SystmOne IT system can use a yellow card reporting feature that interacts directly with the MHRA database.

Foy said the MHRA had now received 1,008 yellow cards direct from practice IT systems and expected to receive another 500 by the end of 2011.

“In 2010, a total of 2,237 yellow cards were received directly from GPs by all reporting methods,” he said. “An additional 1,500 yellow cards from SystmOne will mean more than a 60% annual increase.”

Foy said the MHRA was now in discussions with the government IT agency NHS Connecting for Health and individual GP IT system providers about introducing electronic yellow card reporting into other GP systems.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs